Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 198

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

Open access
Larkin, James, Del Vecchio, Michele, Mandalá, Mario, Gogas, Helen, Arance Fernandez, Ana M., Dalle, Stéphane, Cowey, Charles Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Marquez-Rodas, Ivan, Butler, Marcus O., Di Giacomo, Anna Maria, Middleton, Mark R., Lutzky, Jose, de la Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew G., Fecher, Leslie A., Millward, Michael, Nathan, Paul D., Khushalani, Nikhil I., Queirolo, Paola, Ritchings, Corey, Lobo, Maurice, Askelson, Margarita, Tang, Hao, Dolfi, Sonia, Ascierto, Paolo A., Weber, Jeffrey · 2023 · Clinical Cancer Research

Abstract

Purpose: In the phase III CheckMate 238 study, adjuvant nivolumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in patients with resected stage IIIB–C or stage IV melanoma, with benefit sustained at 4 years. We report updated 5-year efficacy and biomarker findings. Patients and Methods: Patients with resected stage IIIB–C/IV melanoma were stratified by stage and baseline programmed death cell ligand 1 (PD-L1) expression and received nivolumab 3 mg/kg every 2 weeks or ipilimumab 10 mg/kg every 3 weeks for four doses and then every 12 weeks, both intravenously for 1 year until disease recurrence, unacceptable toxicity, or withdrawal of consent. The primary endpoint was RFS. Results: At a minimum follow-up of 62 months, RFS with nivolumab remained superior to ipilimumab (HR = 0.72; 95% confidence interval, 0.60–0.86; 5-year rates of 50% vs. 39%). Five-year distant metastasis-free survival (DMFS) rates were 58% with nivolumab versus 51% with ipilimumab. Five-year overall survival (OS) rates were 76% with nivolumab and 72% with ipilimumab (75% data maturity: 228 of 302 planned events). Higher levels of tumor mutational burden (TMB), tumor PD-L1, intratumoral CD8+ T cells and IFNγ-associated gene expression signature, and lower levels of peripheral serum C-reactive protein were associated with improved RFS and OS with both nivolumab and ipilimumab, albeit with limited clinically meaningful predictive value. Conclusions: Nivolumab is a proven adjuvant treatment for resected melanoma at high risk of recurrence, with sustained, long-term improvement in RFS and DMFS compared with ipilimumab and high OS rates. Identification of additional biomarkers is needed to better predict treatment outcome. See related commentary by Augustin and Luke, p. 3253

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-22-3145

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 198

Metadata

Authors
Larkin, J., Del Vecchio, M., Mandalá, M., Gogas, H., Arance Fernandez, A. M., Dalle, S., Cowey, C. L., Schenker, M., Grob, J.-J., Chiarion-Sileni, V., Marquez-Rodas, I., Butler, M. O., Di Giacomo, A. M., Middleton, M. R., Lutzky, J., de la Cruz-Merino, L., Arenberger, P., Atkinson, V., Hill, A. G., Fecher, L. A., Millward, M., Nathan, P. D., Khushalani, N. I., Queirolo, P., Ritchings, C., Lobo, M., Askelson, M., Tang, H., Dolfi, S., Ascierto, P. A., & Weber, J.
Venue
Clinical Cancer Research
Published
2023-04-14
Volume
29
Issue
17
Pages
3352-3361
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W4365504267
Cited by
198
References
6
FWCI
20.29
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-22-3145
The paper
Larkin, J., Del Vecchio, M., Mandalá, M., Gogas, H., Arance Fernandez, A. M., Dalle, S., Cowey, C. L., Schenker, M., Grob, J.-J., Chiarion-Sileni, V., Marquez-Rodas, I., Butler, M. O., Di Giacomo, A. M., Middleton, M. R., Lutzky, J., de la Cruz-Merino, L., Arenberger, P., Atkinson, V., Hill, A. G., . . . Weber, J. (2023). Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-22-3145

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.